This results in marked variability in ITP management after first relapse, as reflected here by retained use of platelet transfusion, androgens, and anti‐fibrinolytics, as well as the increased use of other immunosuppressants, cyclosporine, TPO‐RAs, and anti‐CD20. Here, TPO is linked to autoimmune thrombocytopenic purpura.